Third Rock Signs $2B-Plus Pact With Months-Old Chinese AI Biologics Startup Funnel
- Third Rock Ventures struck a partnership worth more than $2 billion with Funnel Biosciences (Fangnuo), a Chinese startup formed only months earlier.
- Funnel's platform pairs generative algorithms with physics-based energy functions to design epitope-guided antibodies from scratch.
- The company was co-founded in February by a former MSD executive and an AI protein-design researcher.
💡 Points Based on public reports
A $2B headline on a months-old company is a biobucks number: expect the upfront to be a small fraction, and the value to depend on whether the platform yields developable molecules. It also shows a US venture builder sourcing AI discovery from China despite the political climate. The thing to check is how much is equity-like option value versus milestones payable on real clinical progress.
📰 Source · pharmaphorum ↗ Third Rock in $2bn drug-hunting pact with China's Funnel